Frontlight ResearchEarly access
TerminatedNo phase
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
Key facts
- Who runs it
- Harbinger Health
- Where
- Kansas City, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 14 people enrolled
- Started
- 20 Mar 2026
- Ended
- 27 Mar 2026
- Type of study
- Observational, 2 groups
- Record updated
- 9 April 2026
- Why it stopped
- Study terminated per sponsor decision due to operational reasons. The termination was not a result of any participant safety concerns.
Who can take part
- Age
- 45 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Cohort 1: Prospective Cohort Inclusion criteria - All Participants must meet the following criteria to be included in the study:; Provide written or electronic informed consent, according to local guidelines, signed and dated by the Participant or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analyses; Age 45 or older at time of consent; Documented positive result from a mt-sDNA test obtained as part of routine clinical care within 12 months of blood draw; Scheduled and intends to undergo a diagnostic colonoscopy within 60 days of consent as part of standard care; Considered by a physician as being of average risk for CRC; Willing to provide an investigational blood draw prior to undergoing bowel preparation administration and colonoscopy
- Cohort 2: Confirmed Case Cohort Inclusion criteria - All Participants must meet the following criteria to be included in the study:; Provide written or electronic informed consent, according to local guidelines, signed and dated by the Participant or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analyses; Age 45 or older at time of consent; Has a confirmed CRC diagnosis within 90 days prior to signing the informed consent form, based on standard diagnostic procedures; Must remain treatment-naïve for the current malignancy (no surgical resection, neoadjuvant chemotherapy, or radiation therapy has occurred since diagnosis)
Who cannot take part
- Cohort 1: Prospective Cohort Exclusion Criteria - Participants who meet any of the following criteria will be excluded from study entry:; Undergoing colonoscopy for investigation of symptoms such as rectal bleeding, blood in stool, or significant recent changes in stool habits; History of CRC or AA diagnosed prior to the index mtsDNA positive test result; History of any malignancy (patients who have undergone surgical removal of skin basal cell or squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of informed consent); Has been diagnosed with a condition associated with a high risk of CRC (including inflammatory bowel disease (IBD), chronic ulcerative colitis, Crohn's disease, or familial adenomatous polyposis) or has a family history of CRC, defined as having a first-degree relative (parent, sibling, or child) with a CRC diagnosis at any age; Has been diagnosed with a relevant familial (hereditary) cancer syndrome that places them above average risk of CRC such as hereditary nonpolyposis CRC syndrome (or Lynch syndrome), Peutz-Jeghers syndrome, MYH-associated polyposis, Gardner's syndrome, Turcot's (or Crail's) syndrome, Cowden's syndrome, juvenile polyposis, Cronkhite-Canada syndrome, neurofibromatosis, or familial hyperplastic polyposis; Is suffering from any febrile illness defined as a temperature >101.5°F within 48 hours preceding the blood draw; Participant is pregnant (self-reported); Recipient of an organ transplant, blood transfusion within 120 days, or prior non-autologous (allogeneic) bone marrow or stem cell transplant (Participants with a corneal transplant can be considered for study entry); Inability or unwillingness to comply with study procedures or follow-up requirements; Previous or current participation in any study sponsored by, or employment with, Harbinger Health; Participation in a clinical research study sponsored by an external organization which may interfere with study procedures or outcomes; Has any condition that in the opinion of the Investigator should preclude participation in the study
- Cohort 2: Confirmed Case Cohort Exclusion Criteria - Participants who meet any of the following criteria will be excluded from study entry:; Has a history of any malignancy (patients who have undergone surgical removal of skin basal cell or squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of informed consent for the study); Is suffering from any febrile illness defined as a temperature >101.5°F within 48 hours preceding the blood draw; Participant is pregnant (self-reported); Is a recipient of an organ transplant, blood transfusion within 120 days, or prior non-autologous (allogeneic) bone marrow or stem cell transplant (Participants with a corneal transplant can be considered for study entry); Inability or unwillingness to comply with study procedures or follow-up requirements; Previous or current participation in any study sponsored by, or employment with, Harbinger Health; Participation in a clinical research study sponsored by an external organization which may interfere with study procedures or outcomes; Has any condition that in the opinion of the Investigator should preclude participation in the study
Where in United States
- Aton HealthKansas City, United States
About the trial
What the trial wants to find out
The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
The 2 groups in the trial
- Cohort 1: Prospective Cohort
Participants with average risk CRC and a positive mt-sDNA test within 12 months of the study blood draw and who are scheduled and intending to undergo a diagnostic colonoscopy within 60 days of consent as part of standard care.
- Cohort 2: Confirmed Case Cohort
Participants with a confirmed colorectal cancer diagnosis at informed consent and who are treatment-naïve for the current malignancy.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study to Evaluate a Blood Based Test to Prioritize Diagnostic Colonoscopy Following a Positive Colorectal Cancer Screening Test (CLEAR Study)
- Record updated
- 9 April 2026